Please use this identifier to cite or link to this item:
Title: Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands
Authors: Diane E.T. Bastiaans
Silvia Forcat
Hermione Lyall
Tim R. Cressey
Rawiwan Hansudewechakul
Suparat Kanjanavanit
Antoni Noguera-Julian
Christoph Konigs
Jamie R.J. Inshaw
Suwalai Chalermpantmetagul
Yacine Saidi
Alexandra Compagnucci
Lynda M. Harper
Carlo Giaquinto
Angela P.H. Colbers
David M. Burger
Keywords: Medicine
Issue Date: 1-Mar-2014
Abstract: © 2013 by Lippincott Williams & Wilkins. Background: Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) are approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) as part of combination antiretroviral therapy. Dosing is based on body weight bands or body surface area under FDA approval and only body surface area by the EMA. This can lead to a different recommended dose. In addition, weight band.based dosing has not been formally studied in the target population. We evaluated the pharmacokinetics (PK) of LPV/r in children, administered twice daily according to the FDA weight bands, using pediatric tablets. Methods: Fifty-three HIV-infected children were included in the PK substudy of the Paediatric European Network for the Treatment of AIDS 18 trial (KONCERT). In this study, children were randomized to receive LPV/r twice or once daily, according to FDA weight bands. A PK assessment was performed in 17, 16 and 20 children in the 15.25 kg, ≥25.35 kg and >35 kg weight band, respectively, while children took the tablets twice daily. Rich sampling was performed, and PK parameters were calculated by noncompartmental analysis. Given the high percentage of Asian children, it was also tested whether there was a difference in PK parameters between Asian and non-Asian children. Results: For the total group, LPV geometric mean AUC0.12, Cmaxand C12were 106.9 h × mg/L, 12.0 mg/L and 4.9 mg/L, respectively. There were no significant differences in LPV PK parameters between the weight bands. In addition, weight was not found to be associated with variability in Cmax, C12or AUC0.12for the LPV PK parameters. Conclusions: FDA weight band.based dosing recommendations provide adequate exposure to LPV when using LPV/r pediatric tablets.
ISSN: 15320987
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.